Talis Biomedical Corporation
Other OTCTotal Valuation
Talis Biomedical Corporation carries a market capitalization of 5.18M, placing it among publicly traded companies globally. Its enterprise value stands at -25.29M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 5.18M |
| Enterprise Value | -25.29M |
Share Statistics
Talis Biomedical Corporation currently has 1.82M shares outstanding.
| Shares Outstanding | 1.82M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 52.57, and the price-to-book ratio stands at -0.03.
| PE Ratio | N/A |
| PS Ratio | 52.57 |
| PB Ratio | -0.03 |
| P/TBV Ratio | 0.32 |
| P/FCF Ratio | -0.39 |
| P/OCF Ratio | -0.39 |
Financial Position
Talis Biomedical Corporation maintains a current ratio of 7.76, meaning it holds 7.8x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 7.76 |
| Quick Ratio | 7.30 |
| Debt / Equity | 38.66 |
| Debt / EBITDA | -0.35 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -52.13 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Talis Biomedical Corporation's stock has gained approximately 77.5% over the past 52 weeks. The 50-day moving average sits at 2.37, while the 200-day moving average is 1.72.
| Beta (5Y) | N/A |
| 52-Week Price Change | 77.5% |
| 50-Day Moving Average | 2.37 |
| 200-Day Moving Average | 1.72 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Talis Biomedical Corporation generated 300,000.00 in revenue and converted that into -51.03M in net income, yielding earnings per share of -28.02. EBITDA reached -54.35M, while operating income came in at -55.12M.
| Revenue | 300,000.00 |
| Gross Profit | 280,000.00 |
| Operating Income | -55.12M |
| Pretax Income | -51.03M |
| Net Income | -51.03M |
| EBITDA | -54.35M |
| EBIT | -55.12M |
| Earnings Per Share (EPS) | -28.02 |
Balance Sheet
Talis Biomedical Corporation holds 59.87M in cash and equivalents against 18.80M in total debt, resulting in a net debt position of -59.87M. Total book value stands at -561.84M, with working capital of 55.41M providing operational flexibility.
| Cash & Cash Equivalents | 59.87M |
| Total Debt | 18.80M |
| Net Debt | -59.87M |
| Equity (Book Value) | -561.84M |
| Book Value Per Share | -308.51 |
| Working Capital | 55.41M |
Cash Flow
Talis Biomedical Corporation produced -40.26M in operating cash flow over the past twelve months. After subtracting 23,000.00 in capital expenditures, free cash flow totaled -40.23M - equivalent to -22.09 per share.
| Operating Cash Flow | -40.26M |
| Capital Expenditures | 23,000.00 |
| Free Cash Flow | -40.23M |
| FCF Per Share | -22.09 |
Margins
Talis Biomedical Corporation operates with a gross margin of 93.33, reflecting its pricing power and cost economics. The operating margin of -18,374.00 and net profit margin of -17,008.67 provide insight into operational efficiency.
| Gross Margin | 93.33 |
| Operating Margin | -18,374.00 |
| Pretax Margin | -17,008.67 |
| Profit Margin | -17,008.67 |
| EBITDA Margin | -18,116.00 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -0.01 |
| FCF Yield | -255.41 |
Stock Splits
Talis Biomedical Corporation's most recent stock split took place on July 6, 2023 with a 15:1 split ratio.
| Last Split Date | 7/6/2023 |
| Split Ratio | 15:1 |
Scores
Talis Biomedical Corporation posts an Altman Z-Score of -12.01, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -12.01 |